Showing results (141-150 of 280) with videos related to
Sort By:
Pageof 28
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.Cancer|September 15, 2018
Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphomaScott F Huntington, Jessica R Hoag, Weiwei Zhu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaSteven D Gore, Ivana Gojo, Mikkael A Sekeres, et al.Digestive Diseases and Sciences|June 10, 2004
In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c miceElizabeth A Griffiths, Linda C Duffy, Floyd L Schanbacher, et al.Leukemia Research|November 17, 2018
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experiencePankit Vachhani, Raed Al Yacoub, Austin Miller, et al.British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.Leukemia & Lymphoma|October 2, 2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agentsAmer M Zeidan, Xin Hu, Weiwei Zhu, et al.American Journal of Hematology|February 5, 2015
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemiaAshkan Emadi, Rawan Faramand, Brandon Carter-Cooper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.Pageof 28